Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Non-Alcoholic Steatohepatitis Biomarkers Market Value Analysis: What Growth Lies Ahead Over The Forecast Period?
The non-alcoholic steatohepatitis biomarkers market has experienced significant expansion in recent years. Its size is anticipated to increase from $1.68 billion in 2025 to $2.08 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 23.2%. Historically, this growth can be ascribed to elements such as the growing prevalence of metabolic disorders, a rise in the incidence of obesity and type 2 diabetes, the broadening of liver disease research programs, the accessibility of advanced diagnostic assays, and increasing pharmaceutical investment in NASH therapies.
The non-alcoholic steatohepatitis biomarkers market size is anticipated to expand significantly in the coming years. This market is projected to reach $4.6 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 22.0%. This expansion during the forecast period is driven by several factors, including heightened investments in precision hepatology, a growing need for non-invasive diagnostic tools, the proliferation of biomarker-driven clinical trials, increasing adoption of personalized medicine strategies, and an enhanced focus on managing diseases in their early stages. Key trends observed for this period encompass the increased development of non-invasive diagnostic biomarkers, a surge in the utilization of serum-based NASH biomarkers, the expanding integration of AI in biomarker analysis, the broader application of companion diagnostics in drug development, and a reinforced emphasis on detecting diseases early.
Get A Free Sample Report With In-Depth Market Insights:
Non-Alcoholic Steatohepatitis Biomarkers Market Demand Drivers Opening New Revenue Streams
The increasing incidence of liver cancer is anticipated to fuel the expansion of the non-alcoholic steatohepatitis biomarkers market in the future. Liver cancer involves the formation of cancerous growths within the liver, originating either within the organ itself (primary liver cancer) or spreading there from other bodily regions (secondary or metastatic liver cancer). Non-alcoholic steatohepatitis (NASH) biomarkers find application in liver cancer for purposes such as early identification, tracking disease advancement, evaluating treatment efficacy, offering prognostic insights, and potentially lessening the requirement for intrusive medical interventions. For example, reports from ecancer medical science, a UK-based cancer journal, in July 2025, indicate that previous forecasts suggest new liver cancer diagnoses will nearly double from 870,000 in 2022 to 1.52 million by 2050. This surge is primarily attributed to demographic expansion and an aging populace, with the most significant increases predicted in Africa. Furthermore, liver cancer fatalities are also forecast to rise from 760,000 in 2022 to 1.37 million by 2050. Consequently, the increasing occurrence of liver cancer is propelling the expansion of the non-alcoholic steatohepatitis biomarkers market.
Non-Alcoholic Steatohepatitis Biomarkers Market Segment Trends And Revenue Contributors
The non-alcoholic steatohepatitis biomarkers market covered in this report is segmented –
1) By Type: Hepatic Fibrosis Biomarkers, Serum Biomarkers, Oxidative Stress Biomarkers, Apoptosis Biomarkers, Other Types
2) By Technology: Enzyme-Linked Immunosorbent Assay (ELISA), Mass Spectrometry, Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), Next-Generation Sequencing (NGS), Other Technologies
3) By End Use: Research Institutes And Academics, Diagnostic Centers, Pharmaceutical Companies And Pharmaceutical Companies And Contract Research Organizations (CROs), Hospitals And Clinics, Other End-Uses
Subsegments:
1) By Hepatic Fibrosis Biomarkers: Hyaluronic Acid, Procollagen III N-terminal Propeptide (PIIINP), Fibrosis-4 (FIB-4) Index
2) By Serum Biomarkers: Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Adiponectin
3) By Oxidative Stress Biomarkers: Malondialdehyde (MDA), 8-Isoprostane, Advanced Oxidation Protein Products (AOPP)
4) By Apoptosis Biomarkers: Caspase-3, Cytochrome c, Liver Inhibitory Protein (LIP)
5) By Other Types: Metabolomic Biomarkers, Genetic Biomarkers, Inflammatory Biomarkers
Non-Alcoholic Steatohepatitis Biomarkers Market Trends Powering Strategic Industry Growth
Major companies within the non-alcoholic steatohepatitis biomarkers market are integrating advanced biomarker platform technologies, such as multi-analyte fibrosis-scoring assays, to improve non-invasive disease assessment and patient risk stratification. These assays analyze multiple fibrosis-related proteins from a single blood sample and employ an algorithm to produce a numerical score, which aids in prognostic evaluation and the identification of advanced fibrosis. For instance, in July 2023, Siemens Healthineers, a Germany-based medical-technology company, was granted breakthrough device designation by the US Food and Drug Administration for the Enhanced Liver Fibrosis Test. This multi-analyte fibrosis-scoring assay is designed to assist in identifying advanced fibrosis and cirrhosis in individuals with non-alcoholic fatty liver disease, generating a numerical score derived from three direct fibrosis biomarkers. The test enables earlier clinical evaluation of liver disease severity, thus reducing the reliance on invasive biopsy.
Non-Alcoholic Steatohepatitis Biomarkers Market Competitive Analysis Of Leading Industry Participants
Major companies operating in the non-alcoholic steatohepatitis biomarkers market are Genfit SA, Prometheus Laboratories Inc., Siemens Medical Solutions USA Inc., BioPredictive, Quest Diagnostics, AstraZeneca Plc., Laboratory Corporation of America Holdings, Pfizer Inc., Bristol-Myers Squibb Company, NGM Biopharmaceuticals Inc., Gilead Sciences Inc., Perspectum Diagnostics Ltd., One Way Liver SL, Enterome SA, Echosens SA, Cisbio Bioassays SAS, Celerion Inc., Boehringer Ingelheim GmbH Inc., Exalenz Bioscience Ltd., Novartis AG, Novo Nordisk A/S, Allergan PLC., Glympse Bio, HistoIndex Pte Ltd, Cirius Therapeutics, Intercept Pharmaceuticals, Viking Therapeutics, Madrigal Pharmaceuticals, Galmed Pharmaceuticals, Immuron Ltd, Metacrine
View The Full Non-Alcoholic Steatohepatitis Biomarkers Market Report:
Non-Alcoholic Steatohepatitis Biomarkers Market Geographic Distribution And Regional Opportunities
North America was the largest region in the non-alcoholic steatohepatitis biomarkers market in 2025. Asia-Pacific is expected to be the fastest-growing region in the non-alcoholic steatohepatitis biomarkers market during the forecast period. The regions covered in the non-alcoholic steatohepatitis biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
